NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

$116.64 +10.60 (+10.00 %)

(As of 04/26/2018 11:12 AM ET)

Previous Close$106.04

Today's Range$109.46 - $116.92

52-Week Range$96.18 - $149.34

Volume2.03 million shs

Average Volume2.14 million shs

Market Capitalization$23.68 billion

P/E Ratio22.49

Dividend YieldN/A

Beta1.13

About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:ALXN

CUSIP01535110

Webwww.alexion.com

Phone475-230-2596

Debt

Debt-to-Equity Ratio0.34%

Current Ratio3.10%

Quick Ratio2.62%

Price-To-Earnings

Trailing P/E Ratio22.49

Forward P/E Ratio19.06

P/E Growth0.95

Sales & Book Value

Annual Sales$3.55 billion

Price / Sales7.30

Cash Flow$8.7964 per share

Price / Cash13.26

Book Value$39.81 per share

Price / Book2.93

Profitability

EPS (Most Recent Fiscal Year)$5.16

Net Income$443.30 million

Net Margins12.48%

Return on Equity12.94%

Return on Assets8.50%

Miscellaneous

Employees2,525

Outstanding Shares222,360,000

How to Become a New Pot Stock Millionaire

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals announced that its Board of Directors has approved a stock buyback plan on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 3.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its shares are undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals (NASDAQ:ALXN) released its earnings results on Wednesday, April, 25th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.50 by $0.18. The biopharmaceutical company had revenue of $930.90 million for the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the company posted $1.38 EPS. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

What price target have analysts set for ALXN?

21 analysts have issued twelve-month target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $120.00 to $180.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $156.5238 in the next year. View Analyst Ratings for Alexion Pharmaceuticals.

What are Wall Street analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

1. According to Zacks Investment Research, "Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. The prospects of ALXN1210 looks good too and a tentative approval will boost the top-line. Alexion is looking to diversify its portfolio and reduce its dependence on its blockbuster drug Soliris. The recently announced Wilson deal will strengthen Alexion’s rare disease pipeline with a late-stage candidate, WTX101 which is currently in phase III for the treatment of Wilson disease, a rare genetic disorder. Earlier, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics among others. Shares of the company have performed better than the industry in the last three months. However, the company relies heavily on Soliris for growth and sales of the same will be impacted by ramp-up of ALXN1210 trials. Pricing will also hit sales." (4/19/2018)
2. JPMorgan Chase analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)

Who are some of Alexion Pharmaceuticals' key competitors?

Some companies that are related to Alexion Pharmaceuticals include AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Mylan (MYL), Teva Pharmaceutical Industries (TEVA) and UCB (UCBJF).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:

Dr. Ludwig N. Hantson, CEO & Director (Age 55)
Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
Ms. Julie O'Neill MBA, Exec. VP of Global Operations (Age 62)
Mr. John B. Moriarty Jr., Former Exec. VP & Gen. Counsel (Age 50)
Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)

Has Alexion Pharmaceuticals been receiving favorable news coverage?

Press coverage about ALXN stock has been trending positive this week, according to Accern. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.39 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $113.56.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $23.68 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.

MarketBeat Community Rating for Alexion Pharmaceuticals (ALXN)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		916 (Vote Outperform)
Underperform Votes:		486 (Vote Underperform)
Total Votes:		1,402

MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Alexion Pharmaceuticals (NASDAQ:ALXN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

21 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $156.5238, suggesting that the stock has a possible upside of 34.19%. The high price target for ALXN is $180.00 and the low price target for ALXN is $120.00. There are currently 1 hold rating and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.95	2.95	2.90	2.83
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 20 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 21 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 19 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 17 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$156.5238	$155.7273	$153.55	$154.8636
Price Target Upside:	34.19% upside	19.16% upside	25.74% upside	14.54% upside

Alexion Pharmaceuticals (NASDAQ:ALXN) Consensus Price Target History

Price Target History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/23/2018	Raymond James	Reiterated Rating	Buy		Low
4/12/2018	Nomura	Boost Price Target	Buy	$165.00	Low
3/16/2018	Credit Suisse Group	Reiterated Rating	Outperform -> Outperform	$147.00 -> $149.00	High
3/15/2018	Robert W. Baird	Set Price Target	Buy	$160.00	Low
3/15/2018	Deutsche Bank	Set Price Target	Buy	$161.00	High
3/9/2018	Cowen	Reiterated Rating	Buy	$163.00	Low
2/12/2018	SunTrust Banks	Set Price Target	Buy	$172.00	Medium
2/9/2018	BMO Capital Markets	Boost Price Target	Outperform -> Outperform	$177.00 -> $180.00	Low
2/9/2018	Stifel Nicolaus	Reiterated Rating	Buy	$151.00	Medium
2/9/2018	Morgan Stanley	Boost Price Target	Overweight -> Overweight	$148.00 -> $151.00	Low
2/9/2018	Leerink Swann	Lower Price Target	Outperform -> Outperform	$166.00 -> $153.00	Low
2/9/2018	Citigroup	Lower Price Target	Buy -> Buy	$173.00 -> $170.00	Low
2/5/2018	Evercore ISI	Upgrade	In-Line -> Outperform		High
1/4/2018	UBS	Downgrade	Strong-Buy -> Outperform		Medium
10/24/2017	Royal Bank of Canada	Boost Price Target		$166.00	N/A
10/23/2017	Piper Jaffray	Reiterated Rating	Overweight -> Overweight	$170.00	N/A
9/5/2017	JPMorgan Chase	Upgrade	Neutral -> Overweight	$163.00 -> $175.00	Medium
7/28/2017	Oppenheimer	Upgrade	Market Perform -> Outperform	$175.00	High
6/9/2017	Goldman Sachs	Reiterated Rating	Buy	$142.00	Low
6/8/2017	Jefferies Group	Set Price Target	Hold	$120.00	Medium
5/24/2017	Barclays	Reiterated Rating	Overweight	$155.00	High
3/30/2017	Instinet	Reiterated Rating	Buy	$148.00	Low
12/13/2016	Wedbush	Reiterated Rating	Neutral	$135.00	N/A
11/30/2016	FBR & Co	Reiterated Rating	Market Perform	$130.00	N/A
10/4/2016	Brean Capital	Initiated Coverage	Buy	$221.00	N/A
6/6/2016	Bank of America	Reiterated Rating	Buy		N/A

(Data available from 4/26/2016 forward)

Alexion Pharmaceuticals (NASDAQ:ALXN) Earnings History and Estimates Chart

Earnings by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) Earnings Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$1.25	$1.37	$1.31

Alexion Pharmaceuticals (NASDAQ ALXN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/26/2018
4/25/2018	Q1 2018	$1.50	$1.68	$920.50 million	$930.90 million	View	N/A
2/8/2018	Q4 2017	$1.09	$1.48	$880.38 million	$909.70 million	View	N/A
10/26/2017	Q3 2017	$1.32	$1.44	$864.34 million	$859.00 million	View	N/A
7/27/2017	Q2 2017	$1.08	$1.56	$846.15 million	$912.00 million	View	N/A
4/27/2017	Q1 2017	$1.05	$1.38	$826.63 million	$870.00 million	View	N/A
2/16/2017	Q416	$1.25	$1.26	$840.69 million	$831.00 million	View	N/A
10/27/2016	Q316	$1.04	$1.23	$787.07 million	$799.00 million	View	Listen
7/28/2016	Q216	$0.91	$1.13	$743.18 million	$753.00 million	View	Listen
4/28/2016	Q116	$1.13	$1.11	$710.98 million	$701.00 million	View	Listen
2/3/2016	Q415	$1.10	$1.13	$703.42 million	$701.00 million	View	N/A
10/29/2015	Q315	$1.01	$1.16	$668.33 million	$666.60 million	View	Listen
7/30/2015	Q215	$1.31	$1.44	$628.03 million	$636.00 million	View	Listen
4/23/2015	Q115	$1.18	$1.28	$594.40 million	$600.30 million	View	N/A
1/29/2015	Q414	$1.17	$1.13	$589.85 million	$599.00 million	View	Listen
10/23/2014	Q314	$1.05	$1.27	$541.93 million	$555.10 million	View	Listen
7/24/2014	Q214	$0.99	$0.99	$509.54 million	$512.50 million	View	Listen
4/24/2014	Q114	$1.26	$1.53	$560.22 million	$566.60 million	View	Listen
1/30/2014	Q413	$0.83	$0.87	$430.08 million	$441.90 million	View	Listen
10/24/2013	Q313	$0.79	$0.83	$395.10 million	$400.40 million	View	Listen
7/25/2013	Q2 2013	$0.68	$0.73	$364.80 million	$370.10 million	View	Listen
4/25/2013	Q1 2013	$0.61	$0.65	$336.56 million	$338.90 million	View	Listen
2/14/2013	Q4 2012	$0.52	$0.60	$316.49 million	$320.50 million	View	Listen
10/24/2012		$0.47	$0.60			View	N/A
7/25/2012		$0.36	$0.47			View	N/A
4/24/2012		$0.38	$0.45			View	N/A
2/9/2012		$0.33	$0.41			View	N/A
10/20/2011		$0.28	$0.37			View	N/A
7/21/2011		$0.26	$0.29			View	N/A
4/21/2011		$0.51	$0.59			View	N/A
2/10/2011		$0.50	$0.51			View	N/A
10/21/2010	Q3 2010	$0.19	$0.15			View	N/A
7/22/2010	Q2 2010	$0.15	$0.16			View	N/A
4/22/2010	Q1 2010	$0.12	$0.11			View	N/A
2/11/2010	Q4 2009	$0.12	$0.12			View	N/A
10/22/2009	Q3 2009	$0.11	$0.15			View	N/A
7/23/2009	Q2 2009	$0.09	$0.11			View	N/A
4/23/2009	Q1 2009	$0.07	$0.08			View	N/A
2/12/2009	Q4 2008	$0.05	$0.08			View	N/A
10/23/2008	Q3 2008	$0.02	$0.11			View	N/A
7/29/2008	Q2 2008	($0.04)	$0.02			View	N/A
4/30/2008	Q1 2008	($0.11)	($0.03)			View	N/A
2/14/2008	Q4 2007	($0.12)	($0.08)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Alexion Pharmaceuticals (NASDAQ:ALXN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.35%
Institutional Ownership Percentage: 94.76%

Insider Trading History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/28/2018	Heidi L Wagner	SVP	Sell	698	$119.35	$83,306.30
2/28/2018	Julie O'neill	EVP	Sell	1,625	$119.83	$194,723.75
2/8/2018	Heidi L Wagner	SVP	Sell	1,774	$116.31	$206,333.94	47,212
2/8/2018	John B Moriarty	EVP	Sell	3,363	$115.70	$389,099.10	71,400
2/8/2018	Ludwig Hantson	CEO	Sell	13,245	$116.31	$1,540,525.95	131,425
2/8/2018	Paul J Clancy	CFO	Sell	6,079	$116.31	$707,048.49	95,093
2/5/2018	Heidi L Wagner	SVP	Sell	655	$117.26	$76,805.30	32,635
2/5/2018	John B Moriarty	EVP	Sell	1,261	$117.26	$147,864.86	20,210
1/2/2018	Ludwig Hantson	CEO	Sell	2,553	$121.63	$310,521.39	36,172
10/2/2017	Heidi L Wagner	SVP	Sell	120	$140.00	$16,800.00
9/5/2017	Ann M Veneman	Director	Sell	835	$145.81	$121,751.35	5,480
9/5/2017	Julie O'neill	EVP	Sell	4,375	$145.44	$636,300.00	26,092
8/28/2017	Julie O'neill	EVP	Sell	11,160	$140.00	$1,562,400.00	26,704
7/31/2017	Ann M Veneman	Director	Sell	700	$137.74	$96,418.00	6,315
6/15/2017	Bros. Advisors Lp Baker	Director	Buy	660,779	$117.33	$77,529,200.07
6/14/2017	Bros. Advisors Lp Baker	Director	Buy	1,348,955	$116.32	$156,910,445.60
6/14/2017	Ludwig Hantson	CEO	Buy	10,000	$116.72	$1,167,200.00	38,725
3/1/2017	Clare Carmichael	EVP	Sell	2,179	$131.66	$286,887.14	33,980
3/1/2017	Heidi L Wagner	SVP	Sell	994	$131.65	$130,860.10	29,646
3/1/2017	Leonard Bell	Director	Sell	3,978	$131.96	$524,936.88	391,910
2/28/2017	Carsten Thiel	EVP	Sell	125	$74.52	$9,315.00	30,197
2/28/2017	Edward Miller	SVP	Sell	590	$131.48	$77,573.20	15,214
2/28/2017	Leonard Bell	Director	Sell	2,738	$131.71	$360,621.98	391,910
2/27/2017	Edward Miller	SVP	Sell	260	$131.20	$34,112.00	15,214
2/27/2017	John B Moriarty	EVP	Sell	612	$131.20	$80,294.40	45,864
2/9/2017	John B Moriarty	EVP	Sell	167	$126.84	$21,182.28	46,476
2/9/2017	Leonard Bell	Director	Sell	246	$126.84	$31,202.64	394,648
2/7/2017	Heidi L Wagner	SVP	Sell	1,932	$125.97	$243,374.04	30,241
2/7/2017	John B Moriarty	EVP	Sell	3,538	$125.79	$445,045.02	46,801
2/7/2017	Leonard Bell	Director	Sell	8,725	$125.97	$1,099,088.25	395,979
1/10/2017	Leonard Bell	Director	Sell	100	$144.99	$14,499.00	403,719
1/9/2017	Leonard Bell	Director	Sell	40,065	$138.48	$5,548,201.20	438,497
1/5/2017	Alvin S Parven	Director	Sell	22,659	$138.35	$3,134,872.65	14,305
12/12/2016	John B Moriarty	EVP	Sell	1,044	$118.61	$123,828.84	50,181
12/9/2016	Carsten Thiel	EVP	Sell	2,308	$130.00	$300,040.00	30,433
11/14/2016	Heidi L Wagner	SVP	Sell	59	$115.10	$6,790.90	31,936
11/4/2016	Leonard Bell	Director	Sell	37,317	$140.38	$5,238,560.46	440,936
10/31/2016	Leonard Bell	Director	Sell	1,300	$135.28	$175,864.00	406,589
10/14/2016	Carsten Thiel	EVP	Sell	4,584	$120.28	$551,363.52	32,741
10/3/2016	Carsten Thiel	EVP	Sell	29	$122.41	$3,549.89	37,325
10/3/2016	Heidi L Wagner	SVP	Sell	120	$122.41	$14,689.20	31,995
9/13/2016	Carsten Thiel	EVP	Sell	3,225	$128.67	$414,960.75	40,354
9/9/2016	Edward Miller	SVP	Sell	367	$128.32	$47,093.44	16,519
9/6/2016	Carsten Thiel	EVP	Sell	1,000	$125.94	$125,940.00	40,579
9/2/2016	Julie O'neill	EVP	Sell	650	$126.29	$82,088.50	35,384
8/30/2016	Clare Carmichael	EVP	Sell	1,000	$127.76	$127,760.00	38,577
8/22/2016	Alvin S Parven	Director	Sell	15,000	$136.53	$2,047,950.00	6,373
8/15/2016	Alvin S Parven	Director	Sell	700	$135.51	$94,857.00	6,373
8/8/2016	Clare Carmichael	EVP	Sell	165	$137.14	$22,628.10	39,577
8/8/2016	David Hallal	CEO	Sell	332	$137.14	$45,530.48	189,266
8/8/2016	Heidi L Wagner	SVP	Sell	222	$137.14	$30,445.08	32,115
8/8/2016	Leonard Bell	Director	Sell	1,010	$137.14	$138,511.40	405,289
8/8/2016	Vikas Sinha	CFO	Sell	277	$137.14	$37,987.78	178,463
6/13/2016	John B Moriarty	EVP	Sell	918	$135.72	$124,590.96	51,360
5/16/2016	Martin Mackay	EVP	Sell	4,097	$139.20	$570,302.40	42,706
5/13/2016	Heidi L Wagner	SVP	Sell	53	$138.65	$7,348.45	32,337
4/1/2016	David Hallal	CEO	Sell	1,414	$135.88	$192,134.32	189,632
2/29/2016	Clare Carmichael	EVP	Sell	1,312	$138.91	$182,249.92	41,054
2/29/2016	David Hallal	CEO	Sell	2,014	$138.93	$279,805.02	193,026
2/29/2016	Edward Miller	SVP	Sell	329	$138.91	$45,701.39	17,215
2/29/2016	Leonard Bell	Director	Sell	3,995	$138.92	$554,985.40	742,222
2/29/2016	Vikas Sinha	CFO	Sell	1,122	$138.91	$155,857.02	179,862
2/8/2016	David Hallal	CEO	Sell	11,297	$140.50	$1,587,228.50	173,026
2/8/2016	Heidi L. Wagner	SVP	Sell	2,108	$140.93	$297,080.44	29,937
2/8/2016	Julie O'neill	EVP	Sell	2,858	$141.83	$405,350.14	30,348
2/8/2016	Leonard Bell	Director	Sell	15,872	$139.58	$2,215,413.76	746,192
2/8/2016	Vikas Sinha	CFO	Sell	6,547	$140.04	$916,841.88	171,862
2/5/2016	Edward Miller	SVP	Sell	1,051	$143.02	$150,314.02	14,215
12/29/2015	Leonard Bell	Director	Sell	35,000	$190.66	$6,673,100.00	749,259
12/17/2015	Leonard Bell	Director	Sell	70,000	$187.69	$13,138,300.00	749,259
12/11/2015	Ann M Veneman	Director	Sell	895	$187.48	$167,794.60	3,252
12/11/2015	John B. Moriarty	EVP	Sell	943	$182.73	$172,314.39	41,340
12/8/2015	Leonard Bell	Director	Sell	70,000	$188.20	$13,174,000.00	849,088
12/8/2015	Saqib Islam	EVP	Sell	950	$190.00	$180,500.00	36,385
11/25/2015	Leonard Bell	Director	Sell	35,000	$181.89	$6,366,150.00	919,088
10/26/2015	Saqib Islam	EVP	Sell	1,558	$168.44	$262,429.52	38,310
9/9/2015	Leonard Bell	Director	Sell	1,050	$180.10	$189,105.00	919,088
6/18/2015	Leonard Bell	Director	Sell	27,835	$179.63	$5,000,001.05
3/19/2015	Leonard Bell	CEO	Sell	15,952	$188.07	$3,000,092.64
3/2/2015	Julie O'neill	EVP	Sell	11,665	$101.49	$1,183,880.85
3/2/2015	Leonard Bell	CEO	Sell	1,230	$180.34	$221,818.20
2/10/2015	Clare Carmichael	EVP	Sell	1,490	$171.15	$255,013.50
2/10/2015	David Hallal	COO	Sell	1,980	$171.15	$338,877.00
2/10/2015	Leonard Bell	CEO	Sell	5,740	$171.15	$982,401.00
2/10/2015	Vikas Sinha	CFO	Sell	1,985	$171.15	$339,732.75
2/9/2015	Clare Carmichael	EVP	Sell	1,665	$173.75	$289,293.75
2/9/2015	David Hallal	COO	Sell	2,920	$173.93	$507,875.60
2/9/2015	Leonard Bell	CEO	Sell	8,660	$173.98	$1,506,666.80
2/9/2015	Vikas Sinha	CFO	Sell	2,703	$174.18	$470,808.54
2/4/2015	David Hallal	COO	Sell	1,373	$174.18	$239,149.14
2/4/2015	Leonard Bell	CEO	Sell	5,223	$174.29	$910,316.67
2/4/2015	Vikas Sinha	CFO	Sell	1,571	$174.19	$273,652.49
12/18/2014	David Hallal	COO	Sell	5,494	$182.03	$1,000,072.82
12/18/2014	Leonard Bell	CEO	Sell	30,415	$179.73	$5,466,487.95
12/18/2014	Vikas Sinha	CFO	Sell	5,493	$182.08	$1,000,165.44
12/9/2014	Leonard Bell	CEO	Sell	133,320	$198.26	$26,432,023.20
12/4/2014	Clare Carmichael	SVP	Sell	10,000	$196.25	$1,962,500.00
12/4/2014	William R Keller	Director	Sell	5,000	$196.25	$981,250.00
12/3/2014	Vikas Sinha	CFO	Sell	75,000	$198.96	$14,922,000.00
11/3/2014	David Hallal	COO	Sell	30,000	$190.01	$5,700,300.00
11/3/2014	Martin Mackay	EVP	Sell	9,375	$191.52	$1,795,500.00
11/3/2014	Saqib Islam	SVP	Sell	28,125	$190.50	$5,357,812.50
11/3/2014	Vikas Sinha	CFO	Sell	49,307	$192.63	$9,498,007.41
10/27/2014	John B Moriarty	SVP	Sell	10,000	$189.49	$1,894,900.00
10/27/2014	Stephen P Squinto	EVP	Sell	5,910	$188.58	$1,114,507.80
10/6/2014	John B Moriarty	SVP	Sell	10,000	$179.00	$1,790,000.00
10/3/2014	Stephen P Squinto	EVP	Sell	10,025	$172.41	$1,728,410.25
9/26/2014	Leonard Bell	CEO	Sell	60,000	$165.12	$9,907,200.00
9/24/2014	Stephen P Squinto	EVP	Sell	76	$159.50	$12,122.00
9/18/2014	Leonard Bell	CEO	Sell	44,435	$160.60	$7,136,261.00
9/10/2014	Leonard Bell	CEO	Sell	12,199	$165.38	$2,017,470.62
9/8/2014	Leonard Bell	CEO	Sell	197,801	$165.32	$32,700,461.32
8/27/2014	Leonard Bell	CEO	Sell	5,912	$169.17	$1,000,133.04
8/25/2014	Andreas Rummelt	Director	Sell	5,052	$170.53	$861,517.56
8/15/2014	Leonard Bell	CEO	Sell	70,000	$167.99	$11,759,300.00
8/13/2014	Leonard Bell	CEO	Sell	105,000	$160.71	$16,874,550.00
8/12/2014	Leonard Bell	CEO	Sell	80,458	$160.16	$12,886,153.28
8/4/2014	David Hallal	EVP	Sell	1,349	$158.00	$213,142.00
8/4/2014	Leonard Bell	CEO	Sell	5,145	$157.88	$812,292.60
8/4/2014	Vikas Sinha	CFO	Sell	1,525	$157.82	$240,675.50
7/30/2014	Leonard Bell	CEO	Sell	127,289	$162.93	$20,739,196.77
7/29/2014	Leonard Bell	CEO	Sell	1,200	$164.93	$197,916.00
7/28/2014	Leonard Bell	CEO	Sell	105,600	$162.38	$17,147,328.00
6/20/2014	Leonard Bell	CEO	Sell	90,280	$163.60	$14,769,808.00
6/12/2014	Martin Mackay	EVP	Sell	25,000	$166.42	$4,160,500.00
6/5/2014	William R Keller	Director	Sell	3,425	$170.00	$582,250.00
5/27/2014	Leonard Bell	CEO	Sell	70,000	$166.16	$11,631,200.00
5/20/2014	Leonard Bell	CEO	Sell	70,000	$155.96	$10,917,200.00	1,032,331
5/14/2014	Martin Mackay	EVP	Sell	3,574	$160.85	$574,877.90	24,426
5/13/2014	Alvin Parven	Director	Sell	12,276	$160.78	$1,973,735.28	4,840
4/29/2014	Leonard Bell	CEO	Sell	70,000	$156.20	$10,934,000.00	1,032,331
2/10/2014	Stephen Squinto	EVP	Sell	7,055	$158.04	$1,114,972.20	101,308
2/7/2014	David Hallal	EVP	Sell	1,620	$155.57	$252,023.40	113,965
2/7/2014	Frank Wright	SVP	Sell	1,098	$155.57	$170,815.86	19,670
2/7/2014	Joseph Madri	Director	Sell	30,000	$159.00	$4,770,000.00	179,217
2/7/2014	Leonard Bell	CEO	Sell	4,620	$155.56	$718,687.20	986,696
2/4/2014	Leonard Bell	CEO	Sell	11,790	$154.50	$1,821,555.00	963,276
2/4/2014	Stephen Squinto	EVP	Sell	36,989	$155.12	$5,737,733.68	94,818
2/4/2014	Vikas Sinha	CFO	Sell	3,552	$154.47	$548,677.44	129,775
1/29/2014	Leonard Bell	CEO	Sell	2,660	$133.81	$355,934.60	975,066
1/29/2014	Stephen Squinto	EVP	Sell	1,118	$133.31	$149,040.58	103,068
1/22/2014	Leonard Bell	CEO	Sell	156,436	$140.80	$22,026,188.80	977,726
1/10/2014	Leonard Bell	CEO	Sell	19,155	$134.98	$2,585,541.90	1,031,957
12/19/2013	Leonard Bell	CEO	Sell	175,000	$126.38	$22,116,500.00	1,031,957
10/28/2013	Stephen P Squinto	EVP	Sell	41,037	$124.06	$5,091,050.22
10/28/2013	Vikas Sinha	CFO	Sell	50,000	$122.97	$6,148,500.00
9/16/2013	Joseph Madri	Director	Sell	30,000	$115.00	$3,450,000.00	179,217
9/16/2013	Leonard Bell	CEO	Sell	3,500	$115.00	$402,500.00	1,026,293
9/13/2013	Stephen Squinto	EVP	Sell	1,000	$114.37	$114,370.00
9/4/2013	Leonard Bell	CEO	Sell	1,850	$110.07	$203,629.50
9/3/2013	Leonard Bell	CEO	Sell	33,150	$110.19	$3,652,798.50	1,003,519
8/30/2013	Clare Carmichael	SVP	Sell	1,237	$107.58	$133,076.46	9,463
8/16/2013	Leonard Bell	CEO	Sell	140,000	$106.08	$14,851,200.00	1,036,669
8/5/2013	Leonard Bell	CEO	Sell	2,919	$116.87	$341,143.53	1,176,669
8/2/2013	Stephen P Squinto	EVP	Sell	14,125	$115.33	$1,629,036.25
7/30/2013	Leonard Bell	CEO	Sell	212,737	$114.62	$24,383,914.94
7/30/2013	Stephen P Squinto	EVP	Sell	1,120	$110.86	$124,163.20
7/12/2013	David Hallal	EVP	Sell	50,000	$120.00	$6,000,000.00
7/1/2013	Stephen P Squinto	EVP	Sell	44,125	$94.97	$4,190,551.25
5/22/2013	R Douglas Norby	Director	Sell	40,000	$102.77	$4,110,800.00
5/20/2013	William R Keller	Director	Sell	9,770	$103.00	$1,006,310.00
5/14/2013	Leonard Bell	CEO	Sell	31,113	$105.74	$3,289,888.62
5/13/2013	Leonard Bell	CEO	Sell	41,220	$100.85	$4,157,037.00
4/10/2013	Leonard Bell	CEO	Sell	26,700	$100.24	$2,676,408.00
2/4/2013	Leonard Bell	CEO	Sell	11,880	$96.27	$1,143,687.60
2/4/2013	Stephen P Squinto	EVP	Sell	2,572	$95.68	$246,088.96
2/4/2013	Vikas Sinha	CFO	Sell	3,483	$95.81	$333,706.23
1/15/2013	Leonard Bell	CEO	Sell	35,000	$98.58	$3,450,300.00
10/31/2012	Patrice Coissac	SVP	Sell	84,764	$91.16	$7,727,086.24

(Data available from 1/1/2013 forward)

Alexion Pharmaceuticals (NASDAQ ALXN) News Headlines

Source:

Date	Headline
	Alexion Pharmaceuticals (ALXN) Updates FY18 Earnings Guidance www.americanbankingnews.com - April 26 at 10:58 AM
	Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates www.zacks.com - April 26 at 8:15 AM
	Alexion Pharmaceuticals beats by $0.18, beats on revenue seekingalpha.com - April 26 at 8:15 AM
	Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study finance.yahoo.com - April 26 at 8:15 AM
	Alexion: 1Q Earnings Snapshot finance.yahoo.com - April 26 at 8:15 AM
	$1.48 EPS Expected for Alexion Pharmaceuticals (ALXN) This Quarter www.americanbankingnews.com - April 25 at 5:10 PM
	[$$] New Biotech Grabs Series A for Rare Disease Treatments finance.yahoo.com - April 25 at 8:19 AM
	Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season finance.yahoo.com - April 24 at 5:36 PM
	Alexion Pharmaceuticals' (ALXN) Buy Rating Reaffirmed at Raymond James www.americanbankingnews.com - April 24 at 8:20 AM
	Alexion Pharma's (ALXN) 4/26 Earnings Will Focus On Brazil - Goldman www.streetinsider.com - April 24 at 8:18 AM
	Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy? April 23, 2018 www.zacks.com - April 24 at 8:18 AM
	Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy? finance.yahoo.com - April 23 at 8:14 AM
	BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil www.reuters.com - April 22 at 8:16 AM
	Alexion Pharma (ALXN) Defended at Leerink www.streetinsider.com - April 22 at 8:16 AM
	Alexion Pharmaceuticals' (ALXN) Buy Rating Reiterated at UBS www.americanbankingnews.com - April 20 at 9:46 PM
	UBS Reiterates Buy Rating for Alexion Pharmaceuticals (ALXN) www.americanbankingnews.com - April 20 at 5:52 PM
	Implications from Soliris patent ruling in Brazil likely immaterial says Alexion seekingalpha.com - April 20 at 5:22 PM
	Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris (Eculizumab) www.finanznachrichten.de - April 20 at 5:22 PM
	Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab) finance.yahoo.com - April 20 at 5:22 PM
	Alexion Slips On Reports Brazil Will Allow Copycats Of Blockbuster Soliris finance.yahoo.com - April 20 at 5:22 PM
	Alexion Pharmaceuticals (ALXN) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - April 20 at 1:26 AM
	Alexion Pharmaceuticals (ALXN) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 19 at 11:46 AM
	Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, Alder Biopharma, and Alexion Pharma www.bizjournals.com - April 19 at 8:14 AM
	Q1 2018 EPS Estimates for Alexion Pharmaceuticals Boosted by Analyst (ALXN) www.americanbankingnews.com - April 19 at 6:28 AM
	Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer www.businesswire.com - April 18 at 8:15 AM
	B.Riley/FBR Downgrades Alexion Pharmaceuticals (ALXN) to Neutral Following Acquisition of Wilson Therapeutics www.streetinsider.com - April 18 at 8:15 AM
	Alexion Pharmaceuticals (ALXN) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - April 18 at 3:28 AM
	Alexion Pharmaceuticals (ALXN) Upgraded at BidaskClub www.americanbankingnews.com - April 16 at 12:03 PM
	Alexion Pharmaceuticals Forecasted to Earn Q1 2018 Earnings of $1.25 Per Share (ALXN) www.americanbankingnews.com - April 16 at 1:44 AM
	Alexion Pharmaceuticals (ALXN) Upgraded to "Strong-Buy" at Zacks Investment Research www.americanbankingnews.com - April 14 at 10:19 AM
	Alexion Spruces Up Its Pipeline With $855 Million Buy Of Rare Disease Drug Maker seekingalpha.com - April 13 at 8:18 AM
	Blog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson Therapeutics finance.yahoo.com - April 13 at 8:18 AM
	Alexion Pharmaceuticals (ALXN) PT Raised to $165.00 at Nomura www.americanbankingnews.com - April 12 at 10:46 AM
	Your Daily Pharma Scoop: Paratek Update, Alexion Acquisition, Arrowhead Data seekingalpha.com - April 12 at 8:33 AM
	Alexion Joins The Biotech M&A Bonanza seekingalpha.com - April 12 at 8:33 AM
	Alexion Pharmaceuticals (ALXN) PT Raised to $113 at Jefferies on Plan to Acqurie WTX101 www.streetinsider.com - April 11 at 5:33 PM
	Why Alexion Pharmaceuticals Inc (NASDAQ:ALXN) May Not Be As Efficient As Its Industry finance.yahoo.com - April 11 at 5:33 PM
	How Alexion Could Diversify From Its Cash Cow To Battle Valeant, Teva finance.yahoo.com - April 11 at 5:33 PM
	Alexion Pharma To Buy Sweden's Wilson Therapeutics For $855 Mln In Cash www.nasdaq.com - April 11 at 8:29 AM
	Biotech M&A rolls on as Alexion snaps up Wilson for $855 million www.reuters.com - April 11 at 8:29 AM
	Alexion Pharma (ALXN) Agrees to Acquire Wilson Therapeutics for $855M www.streetinsider.com - April 11 at 8:29 AM
	Alexion to Acquire Wilson Therapeutics finance.yahoo.com - April 11 at 8:29 AM
	Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln finance.yahoo.com - April 11 at 8:29 AM
	[$$] Alexion Makes Bid for Sweden's Wilson Therapeutics finance.yahoo.com - April 11 at 8:29 AM
	Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln finance.yahoo.com - April 11 at 8:29 AM
	BidaskClub Lowers Alexion Pharmaceuticals (ALXN) to Buy www.americanbankingnews.com - April 10 at 4:29 PM
	Alexion Pharmaceuticals (ALXN) Upgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - April 10 at 12:01 PM
	$919.03 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter www.americanbankingnews.com - April 10 at 2:36 AM
	Alexion Pharmaceuticals, Inc. Is Researching a Turnaround investorplace.com - April 9 at 1:48 PM
	Alexion Pharmaceuticals (ALXN) Stock Rating Upgraded by JPMorgan Chase www.americanbankingnews.com - April 9 at 1:19 PM

Alexion Pharmaceuticals (NASDAQ:ALXN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Alexion Pharmaceuticals (NASDAQ:ALXN) Income Statement, Balance Sheet and Cash Flow Statement

Alexion Pharmaceuticals (NASDAQ ALXN) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff